Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The trial will compare the effect on disease control and immunosuppression treatment of
adding simvastatin 80mg once daily, over a follow-up and treatment period of 2 years.
Patients will be randomised in a 1:1 fashion to standard treatment with placebo or standard
treatment with the addition of simvastatin (80mg daily). They will be followed at 3 months
intervals for 2 years with a primary end point of mean reduction in corticosteroid dosage at
the 12 month follow-up visit.